At the news
? NEUTRALIMPACT 5/10 8-K filed May 7, 2026 at 08:12 ET
Delcath Systems reported Q1 2026 revenue of $25.0M (+26% YoY), beating the $23.4M consensus, but posted a GAAP net loss of $1.1M vs net income of $1.1M a year ago. The company maintained its FY2026 revenue guidance of at least $100M and highlighted 36% HEPZATO volume growth and the CHOPIN trial publication in The Lancet Oncology as key catalysts.
- Q1 2026 total revenue of $25.0M, up 26% from $19.8M in Q1 2025
- GAAP net loss of $1.1M vs net income of $1.1M in Q1 2025
- GAAP diluted EPS of -$0.03 vs $0.03 in Q1 2025
- Non-GAAP adjusted EBITDA of $3.4M, down from $7.6M in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access